RightFit
RecruitingNot applicable

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
Male only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: MRI scans, Biopsies

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests software that helps doctors read images of the prostate. It is for people with known or suspected prostate cancer who are scheduled for an MRI scan and a biopsy guided by MRI images. Taking part lasts about 12 months and includes one MRI scan, 1–2 biopsies, and follow-up.

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You have known or suspected prostate cancer.
  • You have been referred for a prostate MRI scan, followed by a fusion biopsy. This biopsy uses MRI images to help guide the removal of small tissue samples.
  • You freely agree to take part and sign a consent form before the MRI.

Who can't join

  • You cannot give written consent to take part.
  • You cannot follow the study steps or communicate with the researcher.
  • You have a mental health condition that keeps you from giving consent for yourself. Other mental health conditions do not rule you out.
  • You are a prisoner.
  • You are under 18 years old.
  • You have had prostate cancer treatment, such as surgery, radiation, treatment to destroy a small area of tissue, hormone treatment, or chemotherapy.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate. * Voluntary written informed consent before the MRI examination. Exclusion Criteria: * Subjects incapable of giving informed written consent. * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. * Prisoners. * Minor children (under the age of 18 years old). * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

Study sites (2)

IL

OR